Brief: Rg6501 (Opregen®) Phase 1/2A Clinical Results To Be Presented At 2023 Retinal Cell And Gene Therapy Innovation Summit
20/03/2023 12:08
March 20 (Reuters) - Lineage Cell Therapeutics Inc
LCTX.A :
* RG6501 (OPREGEN®) PHASE 1/2A CLINICAL RESULTS TO BE
PRESENTED AT
2023 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT
Source text for Eikon: ID:nBwDgqHca
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million